Peter Anastasiou, Capsida CEO
January 4, 2023 07:45 AM ESTUpdated 10:48 AM
Deals
R&D
Pharma

Cap­si­da makes $55M deal with Eli Lil­ly to de­vel­op gene ther­a­pies

Drew Armstrong

Executive Editor

Cap­si­da Bio­ther­a­peu­tics has added an­oth­er Big Phar­ma part­ner for its gene ther­a­py plat­form, strik­ing a deal with Eli Lil­ly to de­vel­op ther­a­pies for cen­tral ner­vous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times